Personalized Oncology

Integrated Genomic Diagnostics

  • Evaluates the key characteristics of the patient’s tumor through next-generation sequencing (NGS) as well as the patient’s metabolic profile (the potential drug/gene and drug/drug interactions) through pharmacogenomics testing (PGx)
  • Additional diagnostics are available to monitor a patient’s response once therapy has begun
  • AccessDX participates in a myriad of clinical studies, research initiatives and partnerships to extend the field of genomics

Actionable Intelligence and Reporting

  • AccessDX provides physicians and patients with immediately actionable, comprehensive reports
  • Specific diagnostic results, by testing relevant markers, enable physicians to quickly make decisions and identify appropriate therapy
  • Easy-to-understand reports with every step thoughtfully considered
  • Alternative drug assessment also available for the most commonly used drugs

Clinical Implications and Drug Monitoring

  • Proactive, predictive recommendations — following the initial diagnostics and reports, our certified molecular biologists, pathologists and technologists continuously discuss the clinical implications with physicians
  • Drug monitoring services — providing information on whether drug dosage adjustment is needed
  • PharmD call center available to all physicians 

Discover the Integrated Genomic Solution

Redefine the patient journey with an intuitive, powerful combination of next-generation sequencing (NGS) and pharmacogenomics testing (PGx) — a new approach that AccessDX research shows helps enhance and extend patient lives.

No two tumors are alike. No two patients are alike.

Many oncologists use NGS alone to support therapy decisions. However, oncologists can maximize cancer therapy by using NGS to evaluate the patient’s tumor, while PGx establishes a clear understanding of the patient’s potential drug/gene and drug/drug interactions to determine effective dose. 

Every Decision Matters 

Oncologists often introduce genomic tests in the later stages of cancer. However, by introducing next-generation sequencing and pharmacogenomics testing early in the patient’s journey, AccessDX insights show that it can help enhance and extend a patient’s life.

Introducing genomic tests at the beginning stages enables physicians to be proactive and predictive in a patient’s cancer treatment. 

Clinical Implications and Drug Monitoring 

We go beyond the report. Following the initial diagnostics and reports, our staff continuously discusses the clinical implications, giving proactive, predictive recommendations to help physicians improve diagnosis and optimize therapy decisions. AccessDX also offers continual monitoring services and provides information on whether drug dosage adjustment is needed. Our PharmD call center is available to all physicians.